Tirzepatide is not always more expensive than semaglutide, and the price gap between them is smaller than many people assume. For diabetes, Mounjaro (tirzepatide) runs about $1,094 per month at list price, while Ozempic (semaglutide) comes in around $1,011. For weight loss, the picture actually flips: Zepbound (tirzepatide) lists at roughly $1,086 per month, while Wegovy (semaglutide) has historically been priced higher, around $1,349. The real answer to this question depends on which versions you’re comparing and what you actually pay after insurance, coupons, and discount programs.
How List Prices Actually Compare
The perception that tirzepatide costs significantly more than semaglutide likely comes from comparing diabetes medications specifically. Mounjaro’s list price sits about $80 per month above Ozempic’s. That’s a real difference, but it’s roughly an 8% premium, not the dramatic gap many people expect.
On the weight loss side, Eli Lilly priced Zepbound to undercut Wegovy by a meaningful margin when it launched. At list price, Zepbound costs about $260 less per month than Wegovy. Novo Nordisk had the weight loss market largely to itself for a period before Zepbound’s approval, and that first-mover advantage showed up in Wegovy’s pricing. Once Lilly entered as a competitor, it chose a lower price point as a strategy to win market share. So if you’re looking at weight loss prescriptions, tirzepatide is actually the cheaper option at list price.
Neither of these list prices reflects what most patients pay. Insurance coverage, formulary placement, and manufacturer discount programs create wildly different out-of-pocket costs depending on your specific situation.
Why Tirzepatide Carries a Premium for Diabetes
Tirzepatide is a newer and mechanistically different drug. While semaglutide activates one hormone pathway (GLP-1), tirzepatide activates two: GLP-1 and GIP. This dual-action approach is genuinely novel and required its own extensive clinical trial program to prove safety and efficacy. Eli Lilly prices Mounjaro to reflect that differentiation. In head-to-head trials, tirzepatide produced greater reductions in blood sugar and body weight than semaglutide, and pharmaceutical companies routinely price drugs higher when clinical data supports superior outcomes.
There’s also the matter of recouping enormous manufacturing investments. Lilly has committed more than $18 billion to building out production capacity, including a $9 billion manufacturing site in Lebanon, Indiana, dedicated to producing the active ingredient for tirzepatide and pipeline medicines. That’s a staggering infrastructure bet. Novo Nordisk has made its own large investments in semaglutide production, but Lilly’s public commitments since 2020 exceed $16 billion in new U.S. and European facilities alone, with an additional $1.2 billion to upgrade existing plants. These costs get built into the price of the drug.
Patent Protection Keeps Both Prices High
Both medications are brand-name drugs with years of patent exclusivity remaining. Novo Nordisk’s U.S. patent on semaglutide is set to expire around 2032. Tirzepatide’s patents extend even further, since it received FDA approval more recently (2022 for Mounjaro, compared to 2017 for Ozempic). Until generic or biosimilar versions become available, neither manufacturer faces direct price competition from copies of their molecule. This is the single biggest reason both drugs cost what they do. The modest price differences between them are strategic positioning choices, not reflections of dramatically different production costs.
What You Actually Pay Varies Enormously
List prices tell only part of the story. Your real cost depends on whether your insurance covers the specific drug, which tier it sits on in your plan’s formulary, and whether you qualify for a manufacturer discount program.
Eli Lilly offers a savings program for Zepbound that brings the cost down to as low as $499 per month for patients with commercial insurance that doesn’t cover the drug. For patients whose insurance does cover Zepbound, copay savings cards can reduce costs further. Novo Nordisk runs similar programs for Wegovy and Ozempic, though the specific discount amounts change frequently.
Insurance formularies play a huge role. Some plans cover Ozempic but not Mounjaro, or Wegovy but not Zepbound, simply based on negotiated rebate deals between the insurer and the manufacturer. If your plan covers one but not the other, the “cheaper” drug is whichever one your insurer agreed to cover, regardless of list price. Many patients end up on a specific medication not because of the sticker price but because of formulary access.
New Pricing Programs May Narrow the Gap
Both manufacturers have faced intense political and public pressure over pricing. A White House initiative announced pricing that would bring Ozempic and Wegovy down from $1,000 and $1,350 per month to $350 through a government discount program. Zepbound would similarly drop from $1,086 to an average of $346 through the same program. If those prices hold, the cost difference between tirzepatide and semaglutide effectively disappears for eligible patients.
Supply has also stabilized. Both tirzepatide and semaglutide were removed from the FDA’s drug shortage list as of early 2026, which means compounding pharmacies that had been producing cheaper copies face new restrictions. This could push more patients toward brand-name versions and make the list price comparison more relevant again for people without strong insurance coverage.
The Bottom Line on Price Differences
The price gap between tirzepatide and semaglutide is relatively small at list price and often nonexistent at the pharmacy counter. For diabetes, tirzepatide costs slightly more, reflecting its newer dual-action mechanism and Lilly’s clinical data showing stronger results. For weight loss, tirzepatide is actually priced below semaglutide at list price. In both cases, the dominant factor keeping prices high isn’t the difference between the two drugs. It’s that both are patent-protected brand-name medications in a market with explosive demand and no generic alternatives yet available.